Mereo BioPharma COVID-19 Information
Our foremost concerns at Mereo are to respect both the health of the osteogenesis imperfecta (“OI”) and alpha-1 antitrypsin deficiency (“Alpha") communities and our clinical trial participants, as well as to acknowledge the pressures that healthcare systems are currently facing due to the COVID-19 pandemic. Our thoughts go out to the people and families directly impacted by this public health crisis; as well as to the healthcare workers in the frontline, taking care of those affected.
Our current activities on setrusumab for the potential treatment of OI are focussed on preparations for the Phase 3 paediatric trial, which we are intending to start in 2H 2020. We currently expect no change to this timeline. Patients who enrolled in our Phase 2b ASTEROID study in OI are in a one-year follow up post-treatment extension phase, and the investigators leading this programme are taking every care and are addressing each person on an individual basis to secure that safety and health are their primary concerns.
Our Phase 2 alvelestat trial is recruiting individuals with alpha-1 antitrypsin deficiency-related lung disease, who are potentially at greater risk from COVID-19 exposure. We have been in contact with the investigators with Alphas in their trial sites. We are confident that every investigator is doing the right thing by his or her Alphas.
Please speak directly to your physician if you have any questions, comments or concerns.
The European Reference Network on Rare Bone Diseases, ERN-BOND, has also established a special section with resources on COVID-19, specifically aimed at patients and clinicians dealing with rare bone diseases. This brings together different European initiatives; together with a subsection containing worldwide COVID-19 guidelines and recommendations developed by health experts and national authorities with the objective of providing immediate support to people with rare diseases affected by COVID-19.
We understand the high unmet medical need in both OI and Alpha-1 and we will be continuing to keep both development programmes moving forward in the best and most timely way possible. We will continue to do this in communication and close collaboration with the Alpha and OI communities, their treating physicians and the research community.